Prognostic Model and Nomogram for Early-Onset Adenoid Cystic Carcinoma of Head and Neck: A Retrospective SEER-Based Analysis DOI Creative Commons
Li Dai, Shizhou Zhang, Yihua Wu

и другие.

Technology in Cancer Research & Treatment, Год журнала: 2023, Номер 22

Опубликована: Янв. 1, 2023

Background Adenoid cystic carcinoma of head and neck (ACCHN) is an uncommon cancers, whose predilection age 40 to 60. Some studies have revealed that early-onset such as colorectal cancers esophageal adenocarcinoma, might present some unique clinicopathological features different prognosis with late-onset ones. However, little known about the ACCHN. This study aimed develop a prognostic nomogram for overall survival (OS) patients younger than Methods Cases ACCHN from 1975 2016 were retrieved SEER-18 program. Demographic, clinical, outcomes data identified further analysis. The caret package was used randomly divide into training cohort validation cohort. A constructed based on univariate multivariate Cox discriminative ability calibration power evaluated by concordance index (C-index), curve, receiver operating characteristic (ROC) curve. Results total 5858 cases selectively SEER program in this study. number 40, which defined study, 825. Based analysis, tumor size, chemotherapy, surgery, stage selected construction predict 10-year OS. C-index 0.792 (95%CI 0.760-0.823) 0.776 0.720-0.832) set, respectively. area under ROC curve values 0.875 0.810-0.940) 0.833(95%CI 0.754-0.912). plot indicated had proper both cohorts. Conclusion novel validated could be applied assisting clinicians more accurately assess young patients, facilitate clinical decision-making subsequent follow-up.

Язык: Английский

Adenoid cystic carcinoma of the salivary glands: a pilot study of potential therapeutic targets and characterization of the immunological tumor environment and angiogenesis DOI Creative Commons
Ioannis Michaelides, Julian Künzel, Tobias Ettl

и другие.

European Archives of Oto-Rhino-Laryngology, Год журнала: 2023, Номер 280(6), С. 2937 - 2944

Опубликована: Март 1, 2023

Adenoid cystic carcinoma (ACC) is a rare type of cancer commonly occurring in salivary glands. It characterized by slow but infiltrative growth, nerve infiltration and overall poor prognosis, with late recurrence distant metastasis. The treatment ACC still limited to surgery and/or (adjuvant) radiotherapy. Till now no promising systemic therapy option exists. However, various studies deliver results after anti-angiogenetic agents, such as anti-EGFR-antibody Cetuximab or Tyrosinkinase inhibitor Lenvatinib.By using immunohistological methods we analyzed compared the macrophage lymphocyte populations, vascularization, PD-L1-status 12 glands.All cases showed significant elevation macrophages M2 polarization higher vascularization normal gland tissue. CD4/CD8 quotient was heterogenous. does not show relevant PD-L1 expression.The predominant could be responsible for elevated already been proved other types, that promote angiogenesis.

Язык: Английский

Процитировано

8
A Precise and Intelligent Nanomedicine for Salivary Adenoid Cystic Carcinoma Treatment by Combining Antivascular Photodynamic Therapy and Neuroinhibitory Chemotherapy DOI
Qian Chen, Lu Han, Jiaxin Wu

и другие.

Advanced Functional Materials, Год журнала: 2023, Номер 34(13)

Опубликована: Дек. 15, 2023

Abstract Salivary adenoid cystic carcinoma (SACC) is one of the most common salivary gland malignancies. Current clinical therapies have limitations and cannot efficiently prevent SACC development metastasis. Hematogenous neural spread are two major routes In this study, a precise intelligent nanomedicine, RCDT, designed to combine antivascular photodynamic therapy neuroinhibitory chemotherapy against SACC. A tumor vessel‐targeted reactive oxygen species (ROS)‐responsive photosensitizer (RC) synthesized by linking cRGD chlorin e6 (Ce6) via bridge between poly(ethylene glycol) diselenide bonds. neural‐targeted pH‐responsive cytotoxic prodrug (DT) conjugating doxorubicin (DOX) with Tet1, neural‐targeting peptide, an acidic‐cleavable hydrazone bond. RC DT assembled form RCDT hydrophobic interactions, thereby shielding Tet1. Under guidance action Ce6, can precisely disrupt vasculature simultaneously disintegrate expose Tet1 rupturing Guided disintegrated be specifically internalized into neurons release DOX exert effects cleaving Using these stepwise dual‐targeting dual‐responsive strategies, suppress growth metastasis

Язык: Английский

Процитировано

7
Assessing the Impact of Charged Particle Radiation Therapy for Head and Neck Adenoid Cystic Carcinoma: A Systematic Review and Meta-Analysis DOI Creative Commons
Mingyu Tan, Yanliang Chen, Tianqi Du

и другие.

Technology in Cancer Research & Treatment, Год журнала: 2024, Номер 23

Опубликована: Янв. 1, 2024

Purpose: Head and neck adenoid cystic carcinoma (HNACC) is a radioresistant tumor. Particle therapy, primarily proton beam therapy carbon-ion radiation, potential radiotherapy treatment for malignancies. This study aims to conduct meta-analysis evaluate the impact of charged particle radiation on HNACC. Methods: A comprehensive search was conducted in Pubmed, Cochrane Library, Web Science, Embase, Medline until December 31, 2022. The primary endpoints were overall survival (OS), local control (LC), progression-free (PFS), while secondary outcomes included treatment-related toxicity. Version 17.0 STATA used all analyses. Results: total 14 studies, involving 1297 patients, analysis. pooled 5-year OS PFS rates HNACC 78% (95% confidence interval [CI] = 66-91%) 62% CI 47-77%), respectively. For patients included, 2-year OS, LC, as follows: 86.1% 95-100%) 77% 73-82%), 92% 84-100%) 73% 61-85%), 76% 68-84%) 55% 48-62%), grade 3 above acute toxicity 22% 13-32%), late 8% 3-13%). Conclusions: has improve raise quality life patients. However, further research optimization are needed due limited availability cost considerations associated with this modality.

Язык: Английский

Процитировано

2
Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review of the last decade DOI

Jiawei Zhou,

Guo Zhao,

Shuhang Wang

и другие.

British Journal of Cancer, Год журнала: 2024, Номер 131(6), С. 1021 - 1031

Опубликована: Авг. 3, 2024

Язык: Английский

Процитировано

2
Advances of Benzimidazole Derivatives as Anticancer Agents: Bench to Bedside DOI Creative Commons
Kashif Haider, Mohammad Shahar Yar

Biochemistry, Год журнала: 2022, Номер unknown

Опубликована: Янв. 14, 2022

Benzimidazole is one of the privileged nitrogen-containing scaffolds known for its versatile diversified role in insecticides, pesticides, dyes, pigments and pharmaceuticals. Due to electron-rich environment, structural features binding potency various therapeutic targets, benzimidazole derivatives exhibit a broad spectrum biological activity that majorly includes antimicrobial, antifungal, analgesics, anti-diabetic anticancer agents. Several bearing drugs are clinically approved; they used indications. For example, Bilastine, Lerisetron, Maribavir Nocodazole most widely benzimidazole-based marketed available as an antihistamine, antiviral antimitotic agent, respectively. Another example recently approved drug Binimetinib Selumetinib, which indicated BRAF mutated melanoma plexiform neurofibromas. Not only this, many late phases clinical development. vast potential scaffold cancer research, medicinal chemists have gained lot attraction explore it more develop novel, highly effective target-specific drugs.

Язык: Английский

Процитировано

12
Successful Treatment with Definitive Concurrent Chemoradiotherapy Followed by Durvalumab Maintenance Therapy in a Patient with Tracheal Adenoid Cystic Carcinoma DOI Open Access
Erika Mikami, Shinji Nakamichi,

Atsuhiro Nagano

и другие.

Internal Medicine, Год журнала: 2023, Номер 62(18), С. 2731 - 2735

Опубликована: Янв. 14, 2023

Adenoid cystic carcinoma (ACC) is a rare type of malignant tracheal tumor originating from the secretory glands. Complete surgical resection current standard care for ACC. However, there have been few case reports chemoradiotherapy unresectable We herein report 28-year-old man with ACC who received concurrent (CCRT) followed by maintenance therapy durvalumab. CCRT was completed good response and safety, patient currently receiving durvalumab as therapy. Durvalumab after can be treatment option patients

Язык: Английский

Процитировано

6
Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study DOI Creative Commons

Lulu Ye,

Lin Zhang,

Rongrong Li

и другие.

Cancer Medicine, Год журнала: 2023, Номер 12(8), С. 9144 - 9155

Опубликована: Фев. 3, 2023

Abstract Background Treatment options are limited for recurrent/metastatic adenoid cystic carcinoma of the head and neck (R/M ACCHN). We aimed to evaluate preliminary results efficacy safety all‐trans retinoic acid (ATRA) combined with low‐dose apatinib in patients R/M ACCHN according a secondary analysis phase II study. Methods Patients from study (NCT02775370) who orally administered 500 milligram (mg) daily until treatment‐related adverse events (AEs) intolerance or progression occurred were eligible inclusion. further treated combination therapy ATRA (25 mg/m 2 /day) (250 mg/day) between March 2019 October 2021 disease (PD). Results A total 16 included nine (56.3%) males aged 35–69 years old. All recruited previously received anti‐angiogenic then withdrew due toxicities occurred. The objective response rate (ORR) control (DCR) 18.8% 100%, respectively. During median follow‐up 23.9 months (range:17.8–31.7 months), 11 (68.8%) developed PD one them died 20.9 months. progression‐free survival (PFS) was 16.3 (95% CI: 7.2–25.4 6‐month, 12‐month, 24‐month PFS rates 81.3%, 33.3%, grade 3 albuminuria ( n = 2, 12.5%) hand‐foot syndrome 1, 6.25%). Conclusion All‐trans might be potential therapeutic option ACCHN. This finding will confirmed by our registered ongoing trial, APLUS (NCT 04433169).

Язык: Английский

Процитировано

5
miR-183-5p overexpression orchestrates collective invasion in salivary adenoid cystic carcinoma through the FAT1/YAP1 signaling pathway DOI

Bing-jun Chen,

Jian Jiang, Tan Li

и другие.

Biochemical and Biophysical Research Communications, Год журнала: 2023, Номер 655, С. 127 - 137

Опубликована: Март 8, 2023

Язык: Английский

Процитировано

5
The GAL/GALR2 axis promotes the perineural invasion of salivary adenoid cystic carcinoma via epithelial‐to‐mesenchymal transition DOI Creative Commons
Jun Wang, Zihui Yang, Yuanyang Liu

и другие.

Cancer Medicine, Год журнала: 2022, Номер 12(4), С. 4496 - 4509

Опубликована: Авг. 29, 2022

Abstract Background Perineural invasion (PNI) is a typical pathological characteristic of salivary adenoid cystic carcinoma (SACC) and other neurotrophic cancers. The mechanism the neural microenvironment controlling tumor progression during PNI process unclear. In present study, we investigated role molecular mechanisms nerve‐derived neuropeptide galanin (GAL) its receptor (GALR2) in regulation SACC. Methods Immunohistochemistry staining clinical association studies were performed to analyze expression GAL GALR2 SACC tissues their value. Dorsal root ganglion or SH‐SY5Y cells co‐cultured with vitro simulate interactions between cells, series assays including transcriptome sequencing, Western blot, Transwell investigate cells. Moreover, both vivo models established assess potential PNI‐specific therapeutic effects by blocking GAL/GALR2 axis. Results highly expressed tissues, associated poor prognosis patients (p < 0.05). Nerve‐derived activated induced epithelial‐to‐mesenchymal transition (EMT) Adding human recombinant co‐culture system promoted proliferation, migration, significantly, but inhibited apoptosis M871, specific antagonist GALR2, significantly blocked above 0.05) Conclusions This study demonstrated that expression, EMT thereby enhancing process. Interruption axis might be novel strategy for anti‐PNI therapy

Язык: Английский

Процитировано

8
HSP27 promotes vasculogenic mimicry formation in human salivary adenoid cystic carcinoma via the AKT-MMP-2/9 pathway DOI
Zhao-Yuan Xu, Jing Han, Kun Yang

и другие.

Oral Surgery Oral Medicine Oral Pathology and Oral Radiology, Год журнала: 2024, Номер 137(5), С. 515 - 528

Опубликована: Март 2, 2024

Язык: Английский

Процитировано

1